| 序号 | 项目编号 | 申报项目名称 年头 | | --- | --- | --- | | 10 | 2025-AISJK-01010 | 面向胃肠肿瘤诊疗的多模态人工智能标准 华中科技大学F | | | | 化数据库 属同济医院 | 据了解，该项目旨在构建高质量、标准化的胃肠肿瘤全周期数据平台，并基于此开发覆盖筛查、分型到疗效预测的AI辅助诊疗系统，目标直指提升我国胃 肠肿瘤的早期发现率和治疗精准度，推动成果转化。 锁定临床真问题，破局临床诊疗关键瓶颈 近日，国内AI医疗头部企业医渡科技(02158)与华中科技大学同济医学院附属同济医院(下称"同济医院")联合申报的胃肠肿瘤诊疗多模态AI数据库项目成功入 选国家工信部2025年人工智能医疗器械创新任务"揭榜挂帅"名单。 工信部"揭榜挂帅"是国家为加速关键核心技术攻关、推动科技成果转化而设立的重大创新机制。本次任务旨在遴选具备强大研发与临床转化能力的团队，集 中破解医疗健康领域的"卡脖子"难题。 胃肠肿瘤在我国发病率与死亡率居高不下，其早期诊断率低、个体化治疗方案选择复杂、预后评估不准等问题，始终是临床面临的严峻挑战。 深化产学研用协同，推动肿瘤诊疗智能发 ...

Group 1 - The project aims to build a high-quality, standardized data platform for the entire cycle of gastrointestinal tumor diagnosis and treatment, developing an AI-assisted diagnostic system to improve early detection rates and treatment precision in China [2][3] - The initiative is part of a national mechanism to accelerate key core technology breakthroughs and promote the transformation of scientific achievements in the healthcare sector [3] - The project is led by a core clinical and research team from Tongji Hospital, supported by Yidu Technology, focusing on integrating multimodal data to enhance AI-driven diagnostic processes [3][4] Group 2 - The technology core of the project is based on "multimodal" and "standardization," aiming to create a comprehensive, high-quality gastrointestinal tumor data asset library that enhances the efficiency of AI product development [4] - The collaboration plans to gather and govern tens of thousands of high-quality case data, developing AI algorithms for early screening, precise classification, efficacy prediction, and recurrence risk assessment [4] - The project will also establish clinical application guidelines and industry standards for AI in gastrointestinal tumor diagnosis and treatment, fostering the development of professionals with both clinical and data science expertise [4][5] Group 3 - Yidu Technology has extensive experience in data governance and multimodal analysis, having served 127 well-known medical institutions and processed nearly 7 billion authorized medical records by September 30, 2025 [5] - The collaboration represents a practical application of an innovative model driven by clinical needs and AI development, aiming to enhance the overall diagnostic level for gastrointestinal tumors in China [5] - The project is expected to contribute to the "Healthy China 2030" initiative by establishing data governance standards and AI development pathways that can be replicated in other major disease areas [5]

2月9日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.77港元的价格回购91万股，总耗 资超500万港元，实现连续第十一个交易日密集回购，累计回购金额约5800万港元，以持续的资本动作 传递对公司价值的认可。 同日港股收盘数据显示，医渡科技股价上涨3.39%，收盘价格报5.79港元，股价同步回暖与连续回购形 成正向呼应，反映市场情绪逐步提振。 近日，花旗发布研报，维持医渡科技"买入"评级，并将其目标价上调至11港元。研报指出，医渡科技已 深度嵌入北京、河南等地的国家级AI医疗应用试点基地项目，并打造了医生Copilot等产品显著提升了 医疗机构运营效率，减轻医护人员负担。与此同时，公司在面向C端推出的"医渡千愈"亦展现出扎实的 技术功底，在花旗开展的多场景测试中，其回答的准确性与医学证据可追溯性表现突出，与蚂蚁阿福、 讯飞晓医等头部产品同处第一梯队，形成To-G(面向政府与医院)与To-C业务的协同布局，为公司长期发 展筑牢根基。 ...

近日，花旗发布研报，维持医渡科技"买入"评级，并将其目标价上调至11港元。研报指出，医渡科技已 深度嵌入北京、河南等地的国家级AI医疗应用试点基地项目，并打造了医生Copilot等产品显著提升了 医疗机构运营效率，减轻医护人员负担。与此同时，公司在面向C端推出的"医渡千愈"亦展现出扎实的 技术功底，在花旗开展的多场景测试中，其回答的准确性与医学证据可追溯性表现突出，与蚂蚁阿福、 讯飞晓医等头部产品同处第一梯队，形成To-G(面向政府与医院)与To-C业务的协同布局，为公司长期发 展筑牢根基。 智通财经APP获悉，2月9日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.77港元的价 格回购91万股，总耗资超500万港元，实现连续第十一个交易日密集回购，累计回购金额约5800万港 元，以持续的资本动作传递对公司价值的认可。 同日港股收盘数据显示，医渡科技股价上涨3.39%，收盘价格报5.79港元，股价同步回暖与连续回购形 成正向呼应，反映市场情绪逐步提振。 ...

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan on February 9, 2026, with an investment of HKD 5.2455 million to repurchase 908,800 shares [1]

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on February 9, spending HKD 5.245 million to repurchase 909,000 shares [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan on February 9, 2026, involving an expenditure of HKD 5.2455 million to repurchase 908,800 shares [1]

FF305 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | ...

Group 1 - The core viewpoint of the article highlights the aggressive share buyback strategy of Yidu Tech (医渡科技), which has repurchased approximately 1.6 million shares at around HKD 5.63 per share, totaling over HKD 9 million, marking the tenth consecutive trading day of buybacks, with a cumulative amount of about HKD 53 million [1] - The company's recent buyback activities demonstrate a "high frequency + high level" characteristic, indicating strong confidence from management in the company's intrinsic value and a clear intention to maintain market capitalization [1] - Citigroup has maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11, anticipating a potential upside of over 96% for the stock price, citing the company's unique advantages in data quality and authority derived from partnerships with top hospitals [1] Group 2 - The business segment targeting government and hospitals shows more predictable profitability compared to consumer applications, benefiting directly from increased AI budgets in hospitals and national project tenders [2] - Based on a solid business model and clear growth trajectory, Citigroup has revised its financial forecasts for the company, projecting a 17% and 30% year-on-year growth in big data platform revenue for fiscal years 2026 and 2027, respectively, with a potential to reach breakeven in fiscal year 2026 [2]

Group 1 - The core viewpoint of the news is that Yidu Tech (02158) has been actively repurchasing its shares, demonstrating confidence in its intrinsic value and a clear intention to maintain its market capitalization [1] - On February 6, the company repurchased approximately 1.6 million shares at around HKD 5.63 per share, with a total expenditure exceeding HKD 9 million, marking the tenth consecutive trading day of intensive buybacks [1] - Cumulatively, the total amount spent on share repurchases has reached approximately HKD 53 million, indicating a consistent and robust buyback strategy [1] Group 2 - Citigroup has maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11, anticipating a potential upside of over 96% for the stock price [1] - The company is recognized for its unique advantage in data quality and authority, stemming from its collaboration with top hospitals, which is crucial for the accuracy of medical AI models [1] - The business segment targeting government and hospitals shows more predictable profitability compared to consumer applications, benefiting directly from increased AI budgets in hospitals and national project tenders [2] Group 3 - Citigroup has revised its financial forecasts for Yidu Tech, projecting a 17% and 30% year-on-year growth in revenue from its big data platform for the fiscal years 2026 and 2027, respectively [2] - The company is expected to reach breakeven in the fiscal year 2026, reflecting a solid business model and clear growth trajectory [2]